bioAffinity Technologies reports skin cancer siRNA preclinical results
Click here to view quick news summary (Spoiler)
Preclinical laboratory data confirms that bioAffinity's novel small interfering RNA (siRNA) architecture selectively kills squamous and basal cell carcinomas in vitro by silencing specific surface receptors, without impacting healthy tissue.
Biotechnology firm bioAffinity Technologies announced preclinical findings showing its novel small interfering RNA therapeutic approach selectively destroys cells from two common skin cancers that affect an estimated 5.4 million annual United States cases.
bioAffinity Technologies announced preclinical results demonstrating that its novel siRNA treatment selectively destroys squamous and basal skin cancer cells in vitro while preserving healthy skin cells. Following the release of the laboratory data, market trading observed the company's shares remaining stable amid early-stage development expectations. The company plans to use these findings to support the development of noninvasive, targeted topical therapies for common skin cancers. While surgical removal is currently the standard treatment for these carcinomas, many patients face a risk of incomplete resection or recurrence that requires additional clinical interventions.
Selective Disruption of Surface Receptors
“Our in vitro findings indicate that silencing specific cell surface receptors was selectively cytotoxic to or impaired the proliferation of squamous skin cancer cells while leaving normal skin cells unaffected,” said bioAffinity Technologies Vice President of Product Development David J. Elzi.
The company noted that these controlled laboratory results have not yet been tested in humans, and no Investigational New Drug application has been submitted to regulators.
While the company plans further research before seeking regulatory review, following the announcement, bioAffinity Technologies' share price was unchanged at $1.50. This current skin cancer research expands upon earlier proprietary findings demonstrating that silencing the specific cell surface receptors CD320 and LRP2 impaired viability across multiple cancer cell lines. The underlying platform technology is protected by United States Patent Number 12,305,171, which was officially issued to the firm in 2025.
